Kontermann RE - Search Results

1

Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.

Schuster L, Seifert O, Vollmer S, Kontermann RE, Schlosshauer B, Hartmann H. Schuster L, et al. Among authors: kontermann re. Mol Pharm. 2015 Sep 8;12(9):3146-57. doi: 10.1021/acs.molpharmaceut.5b00012. Epub 2015 Jul 28. Mol Pharm. 2015. PMID: 26181293

2

Immunoliposomes for cancer therapy.

Kontermann RE. Kontermann RE. Curr Opin Mol Ther. 2006 Feb;8(1):39-45. Curr Opin Mol Ther. 2006. PMID: 16506524 Review.

3

Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.

Baum P, Müller D, Rüger R, Kontermann RE. Baum P, et al. Among authors: kontermann re. J Drug Target. 2007 Jul;15(6):399-406. doi: 10.1080/10611860701453034. J Drug Target. 2007. PMID: 17613658

4

Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling.

Messerschmidt SK, Kolbe A, Müller D, Knoll M, Pleiss J, Kontermann RE. Messerschmidt SK, et al. Among authors: kontermann re. Bioconjug Chem. 2008 Jan;19(1):362-9. doi: 10.1021/bc700349k. Epub 2007 Nov 8. Bioconjug Chem. 2008. PMID: 17988079

5

Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.

Messerschmidt SK, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K, Landfester K, Kontermann RE. Messerschmidt SK, et al. Among authors: kontermann re. J Control Release. 2009 Jul 1;137(1):69-77. doi: 10.1016/j.jconrel.2009.03.010. Epub 2009 Mar 21. J Control Release. 2009. PMID: 19306900

6

Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes.

Rothdiener M, Beuttler J, Messerschmidt SK, Kontermann RE. Rothdiener M, et al. Among authors: kontermann re. Methods Mol Biol. 2010;624:295-308. doi: 10.1007/978-1-60761-609-2_20. Methods Mol Biol. 2010. PMID: 20217604

7

An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.

Kermer V, Baum V, Hornig N, Kontermann RE, Müller D. Kermer V, et al. Among authors: kontermann re. Mol Cancer Ther. 2012 Jun;11(6):1279-88. doi: 10.1158/1535-7163.MCT-12-0019. Epub 2012 Apr 6. Mol Cancer Ther. 2012. PMID: 22491823

8

Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.

Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, Kontermann RE, Pfizenmaier K. Siegemund M, et al. Among authors: kontermann re. Cell Death Dis. 2012 Apr 12;3(4):e295. doi: 10.1038/cddis.2012.29. Cell Death Dis. 2012. PMID: 22495350 Free PMC article.

9

The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.

Seifert O, Plappert A, Heidel N, Fellermeier S, Messerschmidt SK, Richter F, Kontermann RE. Seifert O, et al. Among authors: kontermann re. Protein Eng Des Sel. 2012 Oct;25(10):603-12. doi: 10.1093/protein/gzs059. Epub 2012 Sep 17. Protein Eng Des Sel. 2012. PMID: 22988132

10

Tetravalent antibody-scTRAIL fusion proteins with improved properties.

Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE. Seifert O, et al. Among authors: kontermann re. Mol Cancer Ther. 2014 Jan;13(1):101-11. doi: 10.1158/1535-7163.MCT-13-0396. Epub 2013 Oct 3. Mol Cancer Ther. 2014. PMID: 24092811

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

178 results

Search Page